SCHEMBL18401328

SCHEMBL18401328

CCN(CCN(CCN(CCN(C)CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.56
BLM P54132 2/20 0.56
PMP22 Q01453 2/20 0.56
ALOX15 P16050 2/20 0.56
TSHR P16473 2/20 0.56
CYP2C19 P33261 2/20 0.56
KDM4E B2RXH2 2/20 0.56
LMNA P02545 1/20 0.56
CHRM2 P08172 1/20 0.56
ADRA2A P08913 1/20 0.56
DRD1 P21728 1/20 0.56
SLC6A2 P23975 1/20 0.56
SLC6A4 P31645 1/20 0.56
ADRA1A P35348 1/20 0.56
DRD3 P35462 1/20 0.56
SLC6A3 Q01959 1/20 0.56
HRH3 Q9Y5N1 1/20 0.56
EYA2 O00167 1/20 0.52
APP P05067 1/20 0.52
ACE P12821 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20997750 0.98 TDP1 (0.54) TDP1BLMPMP22ALOX15TSHR
SCHEMBL22766987 0.98 TDP1 (0.54) TDP1BLMPMP22ALOX15TSHR
SCHEMBL29319565 0.96 TDP1 (0.52) TDP1BLMPMP22ALOX15TSHR
SCHEMBL13510839 0.92 TDP1 (0.56) TDP1BLMPMP22ALOX15TSHR
SCHEMBL9387759 0.91 TDP1 (0.56) TDP1BLMPMP22ALOX15TSHR
SCHEMBL14823493 0.91 TDP1 (0.67) TDP1BLMPMP22ALOX15TSHR
SCHEMBL12417263 0.89 TDP1 (0.54) TDP1BLMPMP22ALOX15TSHR
SCHEMBL24177003 0.89 TDP1 (0.71) TDP1BLMPMP22ALOX15TSHR
SCHEMBL13059960 0.89 TDP1 (0.71) TDP1BLMPMP22ALOX15TSHR
SCHEMBL1102344 0.89 TDP1 (0.70) TDP1BLMPMP22ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212549-A1 COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2023-07-06 US disclosed
US-20170258945-A1 LANTHANIDE COMPLEX FORMULATIONS GE HEALTHCARE AS (GB) 2017-09-14 US disclosed
US-9550704-B2 Method for synthesizing radiopharmaceuticals using a cartridge FUTURECHEM CO., LTD. (KR) 2017-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212549-A1 COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF FIBP, FN1, TPX2 TDP1 3724/4885BLM 1576/4885PMP22 4019/4885
US-20170258945-A1 LANTHANIDE COMPLEX FORMULATIONS SLC39A14, ORAI1, SARAF TDP1 3833/4885BLM 3542/4885PMP22 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.